Oxford BioDynamics’ (OBD) House Stock Rating Reiterated at Shore Capital

Shore Capital reaffirmed their house stock rating on shares of Oxford BioDynamics (LON:OBD) in a research report sent to investors on Thursday morning,Digital Look reports.

Oxford BioDynamics Price Performance

LON OBD opened at GBX 0.50 ($0.01) on Thursday. The company has a debt-to-equity ratio of 370.22, a quick ratio of 2.80 and a current ratio of 0.68. The firm’s 50 day moving average price is GBX 0.60 and its 200-day moving average price is GBX 1.73. Oxford BioDynamics has a 52-week low of GBX 0.45 ($0.01) and a 52-week high of GBX 10.60 ($0.14). The company has a market cap of £9.45 million, a PE ratio of -0.09 and a beta of 0.42.

Oxford BioDynamics (LON:OBD) last released its quarterly earnings data on Friday, February 28th. The biotechnology company reported GBX (4.50) (($0.06)) earnings per share (EPS) for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.